Drucker Institute recognizes the organization for its leading role in the fight against pediatric cancer
WASHINGTON, D.C. – Kids v Cancer was awarded the 2015 Peter F. Drucker Award for Nonprofit Innovation for its role in the 2012 Creating Hope Act. Kids v Cancer was chosen out of 655 applicants from nonprofits in 45 states and the District of Columbia.
The award is presented by the Drucker Institute and includes a $100,000 prize, made possible by the Coca-Cola Foundation.
“It is a great honor to be the 2015 recipient of the Peter Drucker Award for Nonprofit Innovation. We will use this recognition and award to continue our efforts to change the landscape of pediatric cancer drug development, including the passing The Advanced Hope Act and Kids Innovative (KIDS) Initiative,” said Nancy Goodman, Executive Director of Kids v Cancer. Since its passage in 2012, four companies have earned Creating Hope Act Rare Pediatric Disease Priority Review vouchers. Most recently, United Therapeutics Corporation announced the sale of its Creating Hope Act priority review voucher to AbbVie for $350 million. United Therapeutics earned the voucher for its development of Unituxin for neuroblastoma.
Since its passage in 2012, four companies have earned Creating Hope Act Rare Pediatric Disease Priority Review vouchers. Most recently, United Therapeutics Corporation announced the sale of its Creating Hope Act priority review voucher to AbbVie for $350 million. United Therapeutics earned the voucher for its development of Unituxin for neuroblastoma, a pediatric cancer.
The Drucker Institute is a social enterprise based at Claremont Graduate University devoted to strengthening organizations to strengthen society. The Drucker Award has been given annually since 1991 to recognize existing programs that meet Peter Drucker’s definition of innovation -“change that creates a new dimension of performance.”
Kids v Cancer is a 501(c)(3) organization focused on changing the landscape of pediatric cancer research by identifying structural impediments at key junctures in the research process – new drugs, tissue donation and access to funding – and developing strategies to address them.